Multivariate analyses of OS and RFS, with baseline MRD status (MRD+ vs MRD−) and treatment arm (oral azacitidine vs placebo) included as covariates
| Parameter . | HR [95% CI] . | P value . |
|---|---|---|
| Overall survival | ||
| Baseline MRD status | 1.85 [1.49, 2.31] | <.0001 |
| MRD+ vs MRD− | ||
| Treatment arm | 0.74 [0.59, 0.92] | .0067 |
| Oral-AZA vs placebo | ||
| Relapse-free survival | ||
| Baseline MRD status | 2.04 [1.65, 2.53] | <.0001 |
| MRD+ vs MRD− | ||
| Treatment arm | 0.63 [0.51, 0.78] | <.0001 |
| Oral-AZA vs placebo |
| Parameter . | HR [95% CI] . | P value . |
|---|---|---|
| Overall survival | ||
| Baseline MRD status | 1.85 [1.49, 2.31] | <.0001 |
| MRD+ vs MRD− | ||
| Treatment arm | 0.74 [0.59, 0.92] | .0067 |
| Oral-AZA vs placebo | ||
| Relapse-free survival | ||
| Baseline MRD status | 2.04 [1.65, 2.53] | <.0001 |
| MRD+ vs MRD− | ||
| Treatment arm | 0.63 [0.51, 0.78] | <.0001 |
| Oral-AZA vs placebo |
AZA, azacitidine; CI, confidence interval; HR, hazard ratio; MRD, measurable residual disease; OS, overall survival; RFS, relapse-free survival.